Functional pentameric formation via coexpression of the Escherichia coli heat-labile enterotoxin B subunit and its fusion protein subunit with a neutralizing epitope of ApxIIA exotoxin improves the mucosal immunogenicity and protection against challenge by Actinobacillus pleuropneumoniae

Clinical and Vaccine Immunology

Volumn 18, Issue 12, 2011, Pages 2168-2177

  Kim, Jung Mi ^a   Park, Seung Moon ^a   Kim, Jung Ae ^a   Park, Jin Ah ^a   Yi, Min Hee ^a   Kim, Nan Sun ^a   Bae, Jong Lye ^a   Park, Sung Goo ^b   Jang, Yong Suk ^a   Yang, Moon Sik ^a   Kim, Dae Hyuk ^a  

^a Chonbuk National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APXIIA NEUTRALIZING EPITOPE EXOTOXIN ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN B FUSION PROTEIN; EPITOPE; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN B; GANGLIOSIDE GM1; UNCLASSIFIED DRUG;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PORCINE PLEUROPNEUMONIA; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

ACTINOBACILLUS INFECTIONS; ACTINOBACILLUS PLEUROPNEUMONIAE; ADMINISTRATION, MUCOSAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; ENTEROTOXINS; EPITOPES; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; HEMOLYSIN PROTEINS; MICE; PROTEIN MULTIMERIZATION; PROTEIN SUBUNITS; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; SURVIVAL ANALYSIS;

EID: 83455210430     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05230-11     Document Type: Article

References (66)

1. Bossé, Y., et al. 2002. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clin. Genet. 62:45-52. (Pubitemid 36372696)
2. Bradford, M. M. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72:248-254.
3. Chia, M. Y., et al. 2011. Evaluation of the immunogenicity of a transgenic tobacco plant expressing the recombinant fusion protein of GP5 of porcine reproductive and respiratory syndrome virus and B subunit of Escherichia coli heat-labile enterotoxin in pigs. Vet. Immunol. Immunopathol. 140:215-225.
4. Clements, J. D. 1990. Construction of a nontoxic fusion peptide for immunization against Escherichia coli strains that produce heat-labile and heatstable enterotoxins. Infect. Immun. 58:1159-1166. (Pubitemid 20151772)
5. de Haan, L., W. Verweij, E. Agsteribbe, and J. Wilschut. 1998. The role of ADT-ribosylation and GM1-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. Immunol. Cell Biol. 76:270-279. (Pubitemid 28281155)
6. Dertzbaugh, M. T., and C. O. Elson. 1993. Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect. Immun. 61:48-55. (Pubitemid 23015398)
7. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
8. Dubreuil, J. D., M. Jacques, K. R. Mittal, and M. Gottschalk. 2000. Actinobacillus pleuropneumoniae surface polysaccharides: their role in diagnosis and immunogenicity. Anim. Health Res. Rev. 1:73-93.
9. Fattal-German, M., and B. Bizzini. 1992. Assessment of the anti-viral effect of a short-term oral treatment of mice with live Saccharomyces cerevisiae cells. Dev. Biol. Stand. 77:115-120.
10. Feil, I. K., et al. 1996. Protein engineering studies of A-chain loop 47-56 of Escherichia coli heat-labile enterotoxin point to a prominent role of this loop for cytotoxicity. Mol. Microbiol. 20:823-832.
11. Fingerut, E., B. Gutter, R. Meir, D. Eliahoo, and J. Pitcovski. 2005. Vaccine and adjuvant activity of recombinant subunit B of E. coli enterotoxin produced in yeast. Vaccine 23:4685-4696. (Pubitemid 41132818)
12. Frey, J., M. Beck, J. F. van den Bosch, R. P. Segers, and J. Nicolet. 1995. Development of an efficient PCR method for toxin typing of Actinobacillus pleuropneumoniae strains. Mol. Cell. Probes 9:277-282.
13. Fuller, T. E., B. J. Thacker, C. O. Duran, and M. H. Mulks. 2000. A genetically-defined riboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine. Vaccine 18:2867-2877. (Pubitemid 30254474)
14. Gietz, R. D., and A. Sugino. 1988. New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. Gene 30:527-534. (Pubitemid 19060666)
15. Haesebrouck, F., K. Chiers, I. Van Overbeke, and R. Ducatelle. 1997. Actinobacillus pleuropneumoniae infections in pigs: the role of virulence factors in pathogenesis and protection. Vet. Microbiol. 58:239-249. (Pubitemid 28026787)
16. Hagiwar, Y., et al. 2001. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine. Vaccine 19:2071-2079. (Pubitemid 32178357)
17. Hames, B. D. 1981. An introduction to polyacrylamide gel electrophoresis, p. 26-42. In B. D. Hames and D. Rickwood (ed.), Gel electrophoresis of proteins, a practical approach. IRL Press, Oxford, United Kingdom.
18. Haq, T. A., H. S. Mason, J. D. Clements, and C. J. Arntzen. 1995. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 268:714-716.
19. Holmgren, J., et al. 2005. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 97:181-188. (Pubitemid 40326949)
20. Ito, H., Y. Fukuda, K. Murata, and A. Kimura. 1983. Transformation of intact yeast cells treated with alkali cations. J. Bacteriol. 153:163-168. (Pubitemid 13119852)
21. Jagusztyn-Krynicka, E. K., J. E. Clark-Curtiss, and R. Curtiss. 1993. Escherichia coli heat-labile toxin subunit B fusions with Streptococcus sobrinus antigens expressed by Salmonella typhimurium oral vaccine strains: importance of the linker for antigenicity and biological activities of the hybrid proteins. Infect. Immun. 61:1004-1015. (Pubitemid 23059661)
22. Kang, T. J., et al. 2004. Enhanced expression of B-subunit of Escherichia coli heat-labile enterotoxin in tobacco by optimization of coding sequence. Appl. Biochem. Biotechnol. 117:175-187.
23. Kang, T. J., S. C. Han, M. S. Yang, and Y. S. Jang. 2006. Expression of synthetic neutralizing epitope of porcine epidemic diarrhea virus fused with synthetic B subunit of Escherichia coli heat-labile enterotoxin in tobacco plants. Protein Expr. Purif. 46:16-22.
24. Katz, D. E., et al. 2003. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 21:341-346. (Pubitemid 36091922)
25. Kim, H. J., et al. 2003. Expression of heteropolymeric ferritin improves iron storage in Saccharomyces cerevisiae. Appl. Environ. Microbiol. 69:1999-2005.
26. Kim, J. M., et al. 2010. Surface-displayed expression of a neutralizing epitope of ApxIIA exotoxin in Saccharomyces cerevisiae and oral administration of it for protective immune responses against challenge by Actinobacillus pleuropneumoniae. Biosci. Biotechnol. Biochem. 74:1362-1367.
27. Kim, S. H., K. W. Seo, J. Kim, K. Y. Lee, and Y. S. Jang. 2010. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J. Immunol. 185:5787-5795.
28. Kim, T. G., et al. 2007. Synthesis and assembly of Escherichia coli heat-labile enterotoxin B subunit in transgenic lettuce (Lactuca sativa). Protein Expr. Purif. 51:22-27.
29. Kim, T. G., M. Y. Kim, and M. S. Yang. 2010. Cholera toxin B subunit-domain III of dengue virus envelope glycoprotein E fusion protein production in transgenic plants. Protein Expr. Purif. 74:236-241.
30. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
31. Lally, E. T., R. B. Hill, I. R. Kieba, and J. Korostoff. 1999. The interaction between RTX toxins and target cells. Trends Microbiol. 7:356-361. (Pubitemid 29421660)
32. Lee, G., et al. 2004. Induction of human IgM and IgG anti-GM1 antibodies in transgenic mice in response to lipopolysaccharides from Campylobacter jejuni. J. Neuroimmunol. 146:63-75. (Pubitemid 38032957)
33. Lee, K. Y., et al. 2006. Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. FEMS Immunol. Med. Microbiol. 48:381-389.
34. Lenser, D. K., T. L. McDonald, and N. G. Miller. 1988. Protection of mice against the lethal effect of an intraperitoneal infection with Haemophilus (Actinobacillus) pleuropneumoniae after vaccination with capsular proteins. Vet. Microbiol. 18:335-348.
35. Lim, J. G., et al. 2009. Expression of functional pentameric heat-labile enterotoxin B subunit of Escherichia coli in Saccharomyces cerevisiae. J. Microbiol. Biotechnol. 19:502-510.
36. Lim, Y. Y., et al. 2001. Enhanced and targeted expression of fungal phytase in Saccharomyces cerevisiae. J. Microbiol. Biotechnol. 11:915-921.
37. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADPribosyltransferase activity. Eur. J. Immunol. 22:2277-2281.
38. Maier, E., N. Reinhard, R. Benz, and J. Frey. 1996. Channel-forming activity and channel size of the RTX toxins ApxI, ApxII, and ApxIII of Actinobacillus pleuropneumoniae. Infect. Immun. 64:4415-4423. (Pubitemid 26357038)
39. Merritt, E. A., et al. 1994. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 3:166-175. (Pubitemid 24086350)
40. Min, K., and C. Chae. 1999. Serotype and apx genotype profiles of Actinobacillus pleuropneumoniae field isolates in Korea. Vet. Rec. 145:251-254. (Pubitemid 129544103)
41. Mo, A. Y., Y. S. Kim, S. M. Park, M. S. Yang, and D. H. Kim. 2005. Expression of fungal phytase on the cell surface of Saccharomyces cerevisiae. Biotechnol. Bioprocess Eng. 10:576-581.
42. Park, E. H., et al. 2000. Expression of glucose oxidase by using recombinant yeast. J. Biotechnol. 81:35-44.
43. Park, S. M., et al. 2005. Expression of the Apx toxins of Actinobacillus pleuropneumoniae in Saccharomyces cerevisiae and its induction of immune response in mice. Biotechnol. Bioprocess Eng. 10:362-366.
44. Park, S. M., et al. 2004. Expression of a functional human tumor necrosis factor (hTNF)-α in yeast Saccharomyces cerevisiae. Biotech. Bioprocess Eng. 9:292-296.
45. Pohl, T. 1990. Concentration of proteins and removal of solutes. Methods Enzymol. 182:68-83. (Pubitemid 20154380)
46. Prideaux, C. T., C. Lenghaus, J. Krywult, and A. L. Hodgson. 1999. Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon. Infect. Immun. 67:1962-1966. (Pubitemid 29144422)
47. Reimer, D., J. Frey, R. Jansen, H. P. Veit, and T. J. Inzana. 1995. Molecular investigation of the role of ApxI and ApxII in the virulence of Actinobacillus pleuropneumoniae serotype 5. Microb. Pathog. 18:197-209.
48. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
49. Santambrogio, P., et al. 1993. Production and characterization of recombinant heteropolymers of human ferritin H and L chains. J. Biol. Chem. 268:12744-12748. (Pubitemid 23182442)
50. Scerbo, M. J., M. J. Bibolini, J. L. Barra, G. A. Roth, and C. G. Monferran. 2008. Expression of a bioactive fusion protein of Escherichia coli heat-labile toxin B subunit to a synapsin peptide. Protein Expr. Purif. 59:320-326.
51. Schellenberg, D., et al. 1994. Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet 343:171-172. (Pubitemid 24028649)
52. Schonberger, O., T. R. Hirst, and O. Pines. 1991. Targeting and assembly of an oligomeric bacterial enterotoxoid in the endoplasmic reticulum of Saccharomyces cerevisiae. Mol. Microbiol. 5:2663-2667.
53. Schreuder, M. P., A. T. Mooren, H. Y. Toschka, C. T. Verrips, and F. M. Klis. 1996. Immobilizing proteins on the surface of yeast cells. Trends Biotechnol. 14:115-120. (Pubitemid 26127524)
54. Seah, J. N., J. Frey, and J. Kwang. 2002. The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice. Infect. Immun. 70:6464-6467. (Pubitemid 35192742)
55. Shin, S. J., et al. 2005. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunol. Med. Microbiol. 43:155-164. (Pubitemid 40170284)
56. Shin, S. J., et al. 2007. Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. J. Vet. Sci. 8:383-392.
57. Shin, Y. M., et al. 2001. Enhanced iron uptake of Saccharomyces cerevisiae by heterologous expression of a tadpole ferritin gene. Appl. Environ. Microbiol. 67:1280-1283.
58. Sixma, T. K., et al. 1991. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 351:371-377. (Pubitemid 21896597)
59. Sixma, T. K., et al. 1992. Lactose binding to heat-labile enterotoxin revealed by X-ray crystallography. Nature 355:561-564.
60. Snider, D. P. 1995. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15:317-348. (Pubitemid 26259134)
61. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622-647.
62. Steinsland, H., et al. 2003. Development and evaluation of genotypic assays for the detection and characterization of enterotoxigenic Escherichia coli. Diagn. Microbiol. Infect. Dis. 45:97-105. (Pubitemid 36263021)
63. Tochikubo, K., and Y. Yasuda. 2000. Principles of mucosal immunity and development of mucosal vaccines using cholera toxin B subunit and its related adjuvants. Rec. Res. Dev. Microbiol. 4:387-405.
64. Tsuji, T., K. Watanabe, and A. Miyama. 1995. Monomer of the B subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli has little ability to bind to GM1 ganglioside compared to its coligenoid. Microbiol. Immunol. 39:817-819.
65. Williams, L. L., M. Fudge, L. S. Burnett, and H. W. Jones. 1992. Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin. Am. J. Clin. Oncol. 15:331-336.
66. Yuki, Y., et al. 2001. Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis. Biotechnol. Bioeng. 74:62-69. (Pubitemid 32606595)